Moderna, Inc.: Working Hard But Competition Is Working Harder

Core Insights - Moderna (NASDAQ: MRNA) went public at $22 in 2018 and remained at this level until 2020, when the COVID-19 pandemic highlighted its potential, leading to a significant price increase of 4,211$11.54 [1] Company Performance - The stock price of Moderna saw a dramatic rise during the COVID-19 pandemic, indicating strong market interest and investor confidence in its vaccine development capabilities [1] Analyst Background - Yavuz Akbay, a quantitative analyst with over 5 years of experience, specializes in interpreting complex financial data and utilizing machine learning algorithms for financial analysis [1]